Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped down prior to trading on Wednesday . The stock had previously closed at $16.00, but opened at $15.40. Ascentage Pharma Group International shares last traded at $15.5150, with a volume of 1,471 shares.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on AAPG shares. Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. BTIG Research reiterated a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Finally, B. Riley Financial assumed coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $46.43.

Ascentage Pharma Group International Stock Down 2.9%

The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22. The stock has a 50-day simple moving average of $18.02 and a 200 day simple moving average of $20.32.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The firm had revenue of $22.24 million during the quarter. As a group, equities research analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 earnings per share for the current year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing therapies that target apoptosis, the natural process of programmed cell death. Its research is directed primarily toward cancer and other serious diseases in which abnormal cell survival contributes to disease progression.

The company’s pipeline includes small-molecule drug candidates designed to inhibit proteins involved in apoptosis regulation, including BCL-2, MDM2 and inhibitor-of-apoptosis proteins.